European Medicines Agency concludes class review of bisphosphonates and atypical fractures (Medical News Today, 15 April 2011)

18 Apr 2011

The European Medicines Agency has concluded that rare atypical fractures of the femur are a class effect of bisphosphonate drugs. The Agency's Committee for Medicinal Products for Human Use (CHMP) said that whilst the drugs' benefits still outweigh their risks in the treatment of osteoporosis, a warning of the risk of these fractures should be added to prescribing information.

Full article

European Medicines Agency concludes class review of bisphosphonates and atypical fractures (Medical News Today, 15 April 2011)

Share this story

Top stories

Most read